Active Ingredient(s): Revefenacin
FDA Approved: * November 9, 2018
Category: Lungs (Pulmonary)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Yupelri Overview

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease that is preventable and treatable. COPD is characterized by long-term respiratory symptoms and airflow limitation.[8] The main symptoms include shortness of breath and a cough which may or may not produce mucus.[4] COPD progressively worsens with everyday activities such as walking or dressing becoming difficult.[3] The two most common conditions of COPD are emph...

Read more Yupelri Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease

Recent Yupelri Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Solution: 175mcg/3ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Yupelri: (1 result)

Sorted by National Drug Code
  • 49502-806 Yupelri 175 ug/3ml Respiratory (Inhalation) Solution by Mylan Specialty L.p.

Other drugs which contain Revefenacin or a similar ingredient: (1 result)